How are biosimilars regulated?
Many countries have established a legal framework to allow approval of biosimilars via an abbreviated registration process. As with all biological medicines, biosimilars are assessed prior to approval by regulatory authorities, for example the European Medicines Agency (EMA). A key component of the regulatory submission for biosimilars is the comparability data derived from thorough analysis of both the biosimilar and the original product to demonstrate that there are no significant differences.
